Skip to main content
BWAY
NASDAQ Industrial Applications And Services

BrainsWay Deep TMS Shows Strong Efficacy in Largest Real-World Study for Comorbid PTSD and Depression

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$14.48
Mkt Cap
$576.031M
52W Low
$5.676
52W High
$17.352
52W Position info
155% above low
Off High info
17% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

BWAY has more than doubled off its 52-week low of $5.676.

Summary

BrainsWay announced positive real-world data from the largest study to date, showing significant improvements in patients with comorbid PTSD and Major Depressive Disorder treated with its Deep TMS technology.


Key Events · Product Development and Regulatory · BWAY

  • Positive Real-World Study Results

    Deep TMS demonstrated an 83.5% response rate for PTSD symptoms and a 66.6% response rate for depression symptoms in patients with comorbid PTSD and MDD.

  • Significant Symptom Reduction

    Patients experienced an average 52% reduction in PTSD symptoms (PCL-5 scores) and a 50% reduction in depression symptoms (PHQ-9 scores).

  • Largest Study to Date

    The findings come from the largest real-world study of Deep TMS for this comorbid condition, involving 462 patients across 11 clinical sites.

  • Future Indication Potential

    While not yet FDA-cleared for this specific indication, these positive results support the potential for future regulatory expansion and market growth.


Analysis · BWAY · Industrial Applications And Services

This filing highlights promising clinical results for BrainsWay's Deep TMS technology in a challenging patient population with both PTSD and major depressive disorder. While Deep TMS is not yet FDA-cleared for this specific comorbid indication, the strong response rates from a large real-world study (83.5% for PTSD symptoms, 66.6% for depression symptoms) provide compelling evidence for its potential. This data strengthens the company's product pipeline and supports future efforts to expand regulatory clearances, potentially opening up a significant new market for its technology.

How filings like this one have moved

In the 30 days to Nov 5, 2026, 43.3% of the 1277 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.16%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BWAY was trading at $14.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $576M. The 52-week trading range was $5.68 to $17.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BWAY - Latest Insights

BWAY
Sep 29, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.48
Real-time Price: $10.60 info
Change: -$2.88 (-21%) info
Market Cap: $449.681M info
BWAY
Aug 27, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.62
Real-time Price: $10.60 info
Change: -$4.02 (-27%) info
Market Cap: $449.681M info
BWAY
Aug 12, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.00
Real-time Price: $10.60 info
Change: -$4.40 (-29%) info
Market Cap: $449.681M info
BWAY
Jun 22, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $14.81
Real-time Price: $10.60 info
Change: -$4.21 (-28%) info
Market Cap: $449.681M info
BWAY
Jun 09, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $14.90
Real-time Price: $10.60 info
Change: -$4.30 (-29%) info
Market Cap: $449.681M info